EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma

Michael Weller, Martin van den Bent, Kirsten Hopkins, Jörg C. Tonn, Roger Stupp, Andrea Falini, Elizabeth Cohen-Jonathan-Moyal, Didier Frappaz, Roger Henriksson, Carmen Balana, Olivier Chinot, Zvi Ram, Guido Reifenberger, Riccardo Soffietti, Wolfgang Wick

Research output: Contribution to journalArticle

321 Citations (Scopus)

Abstract

This guideline provides recommendations for diagnostic and therapeutic procedures for patients with malignant gliomas. We differentiate evidence-based standards from reasonable options or non-evidence-based measures that should no longer be considered. The recommendations herein should provide a framework and assurance for the choice of diagnostic procedures and therapeutic measures and aim to reduce complications from unnecessary treatment and cost. The guideline contributes to a critical appreciation of concurrent drugs with a focus on the controlled use of anticonvulsants and steroids. It should serve as a guideline for all professionals involved in the diagnostics and care of glioma patients and also as a source of knowledge for insurance companies and other institutions involved in the cost regulation of cancer care in Europe. Implementation of the recommendations summarised here will need interdisciplinary structures of care for patients with brain tumours and structured processes of diagnostic and therapeutic procedures.

Original languageEnglish
JournalThe Lancet Oncology
Volume15
Issue number9
DOIs
Publication statusPublished - 2014

Fingerprint

Glioblastoma
Glioma
Guidelines
Patient Care
Insurance
Brain Neoplasms
Health Care Costs
Anticonvulsants
Therapeutics
Steroids
Costs and Cost Analysis
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Cite this

EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. / Weller, Michael; van den Bent, Martin; Hopkins, Kirsten; Tonn, Jörg C.; Stupp, Roger; Falini, Andrea; Cohen-Jonathan-Moyal, Elizabeth; Frappaz, Didier; Henriksson, Roger; Balana, Carmen; Chinot, Olivier; Ram, Zvi; Reifenberger, Guido; Soffietti, Riccardo; Wick, Wolfgang.

In: The Lancet Oncology, Vol. 15, No. 9, 2014.

Research output: Contribution to journalArticle

Weller, M, van den Bent, M, Hopkins, K, Tonn, JC, Stupp, R, Falini, A, Cohen-Jonathan-Moyal, E, Frappaz, D, Henriksson, R, Balana, C, Chinot, O, Ram, Z, Reifenberger, G, Soffietti, R & Wick, W 2014, 'EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma', The Lancet Oncology, vol. 15, no. 9. https://doi.org/10.1016/S1470-2045(14)70011-7
Weller, Michael ; van den Bent, Martin ; Hopkins, Kirsten ; Tonn, Jörg C. ; Stupp, Roger ; Falini, Andrea ; Cohen-Jonathan-Moyal, Elizabeth ; Frappaz, Didier ; Henriksson, Roger ; Balana, Carmen ; Chinot, Olivier ; Ram, Zvi ; Reifenberger, Guido ; Soffietti, Riccardo ; Wick, Wolfgang. / EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. In: The Lancet Oncology. 2014 ; Vol. 15, No. 9.
@article{d05b256159f54fd1b440b1a8f8a3dd73,
title = "EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma",
abstract = "This guideline provides recommendations for diagnostic and therapeutic procedures for patients with malignant gliomas. We differentiate evidence-based standards from reasonable options or non-evidence-based measures that should no longer be considered. The recommendations herein should provide a framework and assurance for the choice of diagnostic procedures and therapeutic measures and aim to reduce complications from unnecessary treatment and cost. The guideline contributes to a critical appreciation of concurrent drugs with a focus on the controlled use of anticonvulsants and steroids. It should serve as a guideline for all professionals involved in the diagnostics and care of glioma patients and also as a source of knowledge for insurance companies and other institutions involved in the cost regulation of cancer care in Europe. Implementation of the recommendations summarised here will need interdisciplinary structures of care for patients with brain tumours and structured processes of diagnostic and therapeutic procedures.",
author = "Michael Weller and {van den Bent}, Martin and Kirsten Hopkins and Tonn, {J{\"o}rg C.} and Roger Stupp and Andrea Falini and Elizabeth Cohen-Jonathan-Moyal and Didier Frappaz and Roger Henriksson and Carmen Balana and Olivier Chinot and Zvi Ram and Guido Reifenberger and Riccardo Soffietti and Wolfgang Wick",
year = "2014",
doi = "10.1016/S1470-2045(14)70011-7",
language = "English",
volume = "15",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "9",

}

TY - JOUR

T1 - EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma

AU - Weller, Michael

AU - van den Bent, Martin

AU - Hopkins, Kirsten

AU - Tonn, Jörg C.

AU - Stupp, Roger

AU - Falini, Andrea

AU - Cohen-Jonathan-Moyal, Elizabeth

AU - Frappaz, Didier

AU - Henriksson, Roger

AU - Balana, Carmen

AU - Chinot, Olivier

AU - Ram, Zvi

AU - Reifenberger, Guido

AU - Soffietti, Riccardo

AU - Wick, Wolfgang

PY - 2014

Y1 - 2014

N2 - This guideline provides recommendations for diagnostic and therapeutic procedures for patients with malignant gliomas. We differentiate evidence-based standards from reasonable options or non-evidence-based measures that should no longer be considered. The recommendations herein should provide a framework and assurance for the choice of diagnostic procedures and therapeutic measures and aim to reduce complications from unnecessary treatment and cost. The guideline contributes to a critical appreciation of concurrent drugs with a focus on the controlled use of anticonvulsants and steroids. It should serve as a guideline for all professionals involved in the diagnostics and care of glioma patients and also as a source of knowledge for insurance companies and other institutions involved in the cost regulation of cancer care in Europe. Implementation of the recommendations summarised here will need interdisciplinary structures of care for patients with brain tumours and structured processes of diagnostic and therapeutic procedures.

AB - This guideline provides recommendations for diagnostic and therapeutic procedures for patients with malignant gliomas. We differentiate evidence-based standards from reasonable options or non-evidence-based measures that should no longer be considered. The recommendations herein should provide a framework and assurance for the choice of diagnostic procedures and therapeutic measures and aim to reduce complications from unnecessary treatment and cost. The guideline contributes to a critical appreciation of concurrent drugs with a focus on the controlled use of anticonvulsants and steroids. It should serve as a guideline for all professionals involved in the diagnostics and care of glioma patients and also as a source of knowledge for insurance companies and other institutions involved in the cost regulation of cancer care in Europe. Implementation of the recommendations summarised here will need interdisciplinary structures of care for patients with brain tumours and structured processes of diagnostic and therapeutic procedures.

UR - http://www.scopus.com/inward/record.url?scp=84904902698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904902698&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(14)70011-7

DO - 10.1016/S1470-2045(14)70011-7

M3 - Article

C2 - 25079102

AN - SCOPUS:84904902698

VL - 15

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 9

ER -